RESEARCH PAPER

Targeting Aging Mechanisms: Pharmacokinetic And Admet Challenges In Senescent Physiology

Sonali K. Diwate[1,2], Suresh G. Killedar[3], Deepak Sawant[2], Rushikesh Kumbhar[2], Vaishnavi Hiremath, Vaishnavi Koulge[2], Anuja More[2], Abhinandan R Patil*[2]

[1*]Department of Pharmaceutics, Research Centre at Tatyasaheb College of Pharmacy, Tatyasaheb Kore Vidyanagari, Kolhapur, Maharashtra, India. 416113.

[2]D.Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, INDIA.

[3]Anandi Pharmacy College, A/P Kalambe, Tarf Kale, Kolhapur, Maharashtra, India. 416205

[4]Department of Quality Assurance Techniques, Bharati Vidyapeeth (Deemed to be University) (BVDU), Poona College of Pharmacy, Pune, India.

[5]Ashokrao Mane College of Pharmacy, Peth Vadgoan, Maharashtra, India.

Corresponding Author:

Abhinandan R. Patil

Department of Pharmaceutics, [2]D.Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, INDIA.

Email: abhisirdyp@gmail.com

ABSTRACT

Natural bioactive agents include flavonoids, mitochondrial-targeted antioxidants, and NAD+ precursors are under growing investigation as well as synthetic agents like dasatinib and rapamycin as promising senotherapeutics due to their ability to control these hallmarks. This broad overview incorporates the mechanistic understanding of the action of both plant-derived and synthetic agents on major aging processes and, in particular, the pharmacodynamics and pharmacokinetics of their actions in aging (or senescence) physiology. The changes in the performance of the CYP450 enzymes, tissue distributions, renal and hepatic clearance as well as gut microbiome composition with age significantly alter the ADMET profile of these agents, which affects the efficacy and safety of these agents. We critically review translational barriers, uncover gaps in age-relevant preclinical models, and suggest strategic solutions on how best to streamline senotherapeutic dosing and delivery system. Through a synthesis of the views of pharmacognosy, molecular geroscience, and translational pharmacology, this synthesis offers a holistic approach to safe and effective interventions that can lengthen healthspan in aging people.

Keywords: Hallmark of aging, Pharmacognosy, Quercetin, ADMET challenges, Senolytics, mTOR inhibitors, NAD+ precursors, Geroprotectors

How to cite this article: Diwate SK, Killedar SG, Sawant D, Kumbhar R, Hiremath V, Koulge V, More A, Patil AR. TARGETING AGING MECHANISMS: PHARMACOKINETIC AND ADMET CHALLENGES IN SENESCENT PHYSIOLOGY. Int J Drug Deliv Technol. 2026;16(15s): 392-397. DOI: 10.25258/ijddt.16.15s.46

INTRODUCTION

Aging and Senescence Pharmacognostic Perspective:

Plants have served as the foundation of anti-aging therapeutic strategies since time immemorial. Natural and synthetic senotherapeutics are now under intense investigation to have overlapping molecular targets but exhibit significant differences in pharmacokinetics, tissue localization and safety profiles, especially in the physiological of the aging process.[1-4]. The review will combine the mechanism and pharmacologic understanding with translational pharmacology to find strategic solutions to optimize anti-aging intervention. **Problems of Botanical Variability and Preparation in Senotherapeutics:**

Plant-based senotherapeutics like quercetin, NAD+ precursors and mitochondrial antioxidants show a great range of variability in phytochemical compositions with regard to genetic, environmental, and agricultural influences, which complicates standardization of doses, yet brings issues of

sustainability, variability between batches and potential contamination.[5,6] Controlled culturing provides chemical homogeneity but can lead to lower phytochemical complexity, which can lead to reduced synergistic interactions. Processing such as drying, grinding and storage environment, extraction methods such as solvent extraction, supercritical fluid extraction and formulation techniques have a strong impact on stability and bioavailability, the choice of solvent selectively extracts specific compounds and absorbs them more in the gastrointestinal tract, which alters the pharmacokinetic profile. More recent innovations in formulation science, especially the delivery systems facilitated by nanotechnology, including liposomes, polymeric nanoparticles, and nanoemulsions, are being used to circumvent solubility and permeability barriers hindering clinical translation of most botanical senotherapeutics.[7-11] Phytochemicals Content Variability. There is a significant change in bioactive compound concentration and profile in different plant cultivars and strains. The genetic factors, environmental conditions like geographic location, soil type, climate, altitude, and season change, agricultural activities including organic and conventional farming, time of fertilization, and pest management approaches have significant implications on the secondary metabolite levels in medicinal plants.[12,13]

Quality Control and Sourcing:

Wild-sourced materials need to be authenticated using strict pharmacognostic tests such as microscopic, macroscopic and phytochemical tests to verify the identity and purity. Growing sources though more predictable, nevertheless demand Good Agricultural and Collection Practices and a post-harvest quality test to address the pharmacopeial standards. **Preparation and Formulation Effects:**

The directly affecting factors of bioactive compounds stability are post-harvest processing methods such as drying techniques, storage conditions, and extract preparation procedures. Flavonoids and other heat-sensitive agents (NAD+ precursors) can be degraded easily in case of excessive heat, humidity, and light exposure in processing and therefore, the extraction solvent (aqueous, ethanol, or methanol), extraction time, and extraction temperature are crucial factors in determining yield and purity of active constituents. The standardization and fractionation procedures are necessary so that the pharmacological effects can be consistent among batches. Plant extracts in most cases need bioavailability improvement measures to enhance absorption and effect. In particular, nanoparticle encapsulation, liposomal encapsulation or complexation methods are especially well suited to ageing populations, with gut function and nutrient absorption showing a great deal of variability.[14-16]

Synthetic Senotherapeutics Integration with Natural Senotherapeutics:

Natural senotherapeutics such as flavonoids and NAD + precursors have multi-targeted modulation of aging pathways, oxidative stress, chronic inflammation, mitochondrial dysfunction, and metabolic dysregulation, and they have a good safety profile and long-term tolerability. Nevertheless, they have issues such as inconsistency in phytochemical levels, poor bioavailability and in other instances, less potent than synthetic drugs. Synthetic senotherapeutics like dasatinib and rapamycin offer effective, specific activities with predictable pharmacokinetics.[17-20] and can have off-target effects, immunosuppressive activity, or metabolic problems leading to toxicity, especially in elderly or frail patients.[23,24]

Integrative Therapeutic Strategies

A complementary approach combining natural product diversity with synthetic precision can maximize therapeutic benefit while minimizing risk.[25-28] Strategic approaches include synergistic combinations pairing lower doses of synthetic senolytics with natural antioxidants to enhance clearance of senescent cells while reducing toxicity, stage-specific deployment introducing synthetic agents during acute phases of senescent cell accumulation followed by natural compounds for long-term maintenance, and innovative co-formulations encapsulating both natural and synthetic agents in shared delivery systems such as nanoparticles or liposomes to improve stability and absorption.

Personalized medicine frameworks using biomarkers, genetic data, and metabolic profiling

allow tailoring of these interventions to individual biological needs, improving safety and efficacy outcomes. [29]

HALLMARKS OF AGING AND THEIR RELEVANCE TO NATURAL PRODUCT PHARMACOLOGY

The hallmarks of aging is a concept popular in geroscience that defines the fundamental, reproducible biological mechanisms that dictate age-associated deterioration. These phenotypes create a system of creating therapeutic targets that may slow, stop, or reverse aging.

Primary Hallmarks

Genomic instability is the damage and mutation that are credited to time, and it degrades the integrity of genes, causing cellular dysfunction, predisposition to cancer, and degeneration by age. The process of telomere attrition (progressive shortening of telomeres with each cell division) constrains the replicative ability of cells and induces a state of cellular senescence. Cellular senescence refers to the condition where injured or stressed cells cease dividing permanently, but still maintain a metabolic state and frequently secrete senescence-associated secretory phenotype factors, which stimulates chronic inflammation and tissue malfunction [30].

Other Interconnected Hallmarks

Other related characteristics are epigenetic changes, such as alterations in DNA methylation and histone modification patterns that disrupt the stability of gene expression, loss of proteostasis with corresponding increasing oxidative stress and loss or dysfunction of stem cells, leading to the loss of regenerative ability, and deregulated intercellular communication with age-related changes in signal molecules that regulate inflammation, immunity, and tissue repair.[31] It is necessary to identify these hallmarks to build multi-targeted interventions. Natural products have the benefit of pleiotropic mechanisms that are specifically adapted to affect multiple hallmarks at the same time, to provide a broad-spectrum approach to anti-aging.

The Need for Therapeutic Strategies and ADMET Evaluation

Special interventions are urgently necessary because of the pivotal position of aging in the development of chronic disease. Examples are senolytics that selectively eliminate senescent cell types like quercetin and dasatinib, mTOR inhibitors like rapamycin that regulate nutrient sensing and lifespan in many experimental models, genomic stability promoters including compounds that promote DNA repair or reduce oxidative DNA damage as well as metabolic health agents such as NAD+ boosters, AMPK activators and mitochondrial antioxidants.[32] Nevertheless, these have to be translated into clinical applications and that has to undergo high-quality ADMET profiling (Absorption, Distribution, Metabolism, Excretion and Toxicity) because aging significantly changes how drugs are dealt with. Pharmacokinetics can slack because liver metabolism can be decreased and kidney clearance can be decreased, whereas pharmacodynamics can alter as receptors, membrane fluidity, and signaling pathways age. In the case of natural products-based interventions, ADMET studies play a critical role in determining bioavailability, possible herb-drug reactions, dose changes in older adults, and long-term safety-related concerns.[33,34]

QUERCETIN AND FLAVONOIDS: SASP MODULATION AND SENOLYSIS

Senesolytics are therapeutic drugs that discriminatively destroy senescent cells, previously irreversible perennial dividers owing to pressures or harm but maintain the ability to be metabolically active. The secretions of these cells include senescence-associated secretory phenotype factors, which include pro-inflammatory cytokines, proteases, and growth factors, which are implicated in chronic inflammation, dysfunction of tissues, and age-related disease development. Dasatinib and quercetin are two senolytics that are under active investigation. Dasatinib is a synthetic tyrosine kinase inhibitor used in the treatment of leukemia, which targets various tyrosine kinases, which are vital to senescent cell survival, leading to apoptosis by inhibiting survival pathways.[35,36] Quercetin is a naturally occurring flavonoid present in onions, apples, berries, and green leafy vegetables, Ginkgo biloba, and Sophora japonica targets many of the essential tyrosine kinases involved in senescent cell survival, and induces apoptosis through inhibition Quercetin interacts and suppresses anti-apoptotic

proteins like Bcl-2 and Bcl-xL, which inhibit mitochondrial-mediated apoptosis in senescent cells. It inhibits pro-survival signaling pathways such as PI3K/Akt/mTOR and STAT3 and down regulates NF-kB signaling, lowering the production of SASP factors, an effect referred to as senomorphism that lowers inflammation without necessarily killing cells.[37-39]

ADMET Considerations

Dasatinib has a wide hepatic metabolism through CYP3A4. Old age lowering of CYP3A4 activity may increase drug plasma levels, which may cause toxicity in the elderly. Safe use in older patients requires dose changes and frequent monitoring due to age-related variations in the composition of gut microbiota and intestinal barrier strength.41 Age-related changes in the composition of gut microbiota and intestinal barrier strength affect the absorption, metabolism, and bioavailability of quercetin. Such differences may contribute to the unpredictable systemic exposure and gastrointestinal side effects and thus personalized dosing approaches will be significant in flavonoid-based senolytic therapy.[40-43]

NAD^+ PRECURSORS FROM DIETARY AND BOTANICAL SOURCES

Nicotinamide adenine dinucleotide (NAD+) is a central cell metabolite and an essential substrate of enzymes that repair DNA, regulate mitochondrial functions, and protect cells against stress. As people age, the level of NAD+ decreases, resulting in the inability to produce energy, instability of the genome, and dysregulation of metabolism. Two significant pathway steps in the NAD + production, nicotinamide riboside and nicotinamide mononucleotide are attractive as healthy aging nutraceuticals.[44,45]

Plant Sources

NMN is found in vegetables such as broccoli, green beans, cucumber, and avocado, while NR is present in wild chicory, bananas, and oranges. Additional dietary sources include tea leaves, potatoes, and members of the Fabaceae family, which contain enzymes that interconvert NMN and NR. These plant-derived precursors can supplement the body's NAD^+ pool, potentially supporting anti-aging biochemical pathways. [46]

Mechanism of Action

The NAD+ precursors restore intracellular NAD+ which triggers sirtuins (NAD+-dependent deacetylases) and other enzymes, including poly(ADP-ribose) polymerases. This increases mitochondrial biogenesis and functioning, maintains genomic stability through DNA repairing, and increases metabolic resilience and stress response capacity.[47,48]

Tissue Penetration and Interindividual Variability

Oral bioavailability and tissue absorption also differ across individuals depending on factors such as aging, gut microbiome composition, and activity of NAD + -metabolizing enzymes like CD38 and nicotinamide phosphoribosyltransferase. Standard oral forms may not be optimal in delivery to some organs particularly to the brain. Individualized dosage and biomarker monitoring can be used to maximize treatment effects.[49]

RAPAMYCIN AND MTOR INHIBITORS

Rapamycin, a central nutrient-sensing kinase, is an antimicrobial drug (macrolide lactone) derived from Streptomyces hygroscopĭ which is a powerful inhibitor of the mechanism that targets rapamycin; it is redox-adapted, anabolic and catabolic processes of close relation to aging. Rapamycin has been shown to inhibit mTOR, thus mimicking the actions of caloric restriction, a known lifespan-prolonging intervention in various species, to suppress cell growth and proliferation pathways, enhance autophagy (recycling of damaged proteins and organelles), and enhance metabolic homeostasis.[50,51]

Natural mTOR Modulators

A number of compounds that are of plant origin also play a role in mTOR signaling. Curcumin in Curcuma longa has anti-inflammatory and AMPK-activating properties that indirectly suppress mTOR.[52] Resveratrol in grapes and red wine activates the SIRT1 and AMPK, and it can affect mTOR signaling. Epigallocatechin gallate of green tea inhibits mTOR through oxidative stress regulation and AMPK stimulation. AMPK is activated by berberine of Coptis chinensis, decreases mTOR and enhances metabolic activity.[53,54]

Mechanism of Action

On binding to the FK506-binding protein 12, rapamycin results in the formation of a complex that inhibits the mTOR complex 1 allosterically. This inhibits the anabolic pathways, restrains the unneeded cell multiplication, and initiates autophagy. Ironically, plant-based modulators are indirectly acting via stimulating the AMPK, adjusting oxidative stress, or down-regulating the inflammatory signals that culminate to mTOR.[55]

Pharmacokinetics and ADMET Considerations

The oral bioavailability of rapamycin is variable because of its excessive metabolism by CYP3A4 and excretion through the transporters P-glycoprotein. Reduced CYP3A4 activity and slower clearance may increase the concentration of drugs in older adults which increases the risk of immunosuppression and infection. Long-term use of plant-derived modulators such as curcumin and resveratrol lacks a good bioavailability because of low absorption, quick metabolism and elimination. Systemic exposure can be enhanced with the help of the strategies like nanoparticles encapsulation, co-delivery with liposomal delivery and co-delivery with bioenhancers.[56-58]

MITOCHONDRIA-TARGETED ANTIOXIDANTS AND POLYPHENOLS

Mitochondrial dysfunction is a key aging hallmark, which is defined by a reduced energy production rate, oxidative stress, and damaged mitochondrial DNA. Mitochondria-targeted antioxidants are substances selected to localize selectively into mitochondria, energy-generating organelles of cells, where oxidative stress is frequently most intense in old age.

Examples and Ethnomedical Roots

Grape skin, peanut, and berry resveratrol are a characteristic substance in the Mediterranean and Persian medicine, where it is traditionally used as wine, grape extracts, and in herbal tonics as a cardiovascular protective and tonifying agent. Curcumin Curcuma longa rhizome curcumin is a foundation of Ayurveda and Southeast Asian medicine, a rasayana (rejuvenative tonic), a control of inflammation, digestion, and age related disorders. In the East Asian conventional medicine, green tea polyphenols, including EGCG, are the key ingredients used daily as a metabolic health-promoting, mind-sharpening, and lifespan-enhancing drink.[59,60]

Traditional Applications

Traditionally, these botanicals were prescribed in case of joint pains, fatigability and cognitive impairments, as agents that would revitalize the blood, energize the life force, and make one younger. These definitions can be well related to their current description as mitochondrial antioxidants involved in the production of cellular energy and oxidative damage.[61]

SENOMORPHICS AND AUTOPHAGY ENHANCERS

Whereas senolytics are directed at the elimination of senescent cells, senomorphics are directed at the regulation of the harmful secretions of these cells, but not necessarily the cell death. The purpose of this strategy is to eliminate negative effects of senescent cells by maintaining beneficial functions of wound healing and tumor suppression and minimizing inflammatory condition and tissue destruction.

Senomorphics

Senomorphics are those agents that repress the production or activation of SASP factors, and reduce the presence of the pro-inflammatory and pro-fibrotic microenvironment that comes with aging. The metformin, a biguanide with wide usage in type 2 diabetes that has been shown to activate AMP-activated protein kinase and suppress NF-kB-mediated SASP synthesis, rapamycin at sub-senolytic doses where mTOR is blocked without inducing cell death, curcumin that inhibits NF-kB and p38 MAPK pathway that suppresses IL-6 and IL-8, and apigenin of parsley and chamomile that suppress SASP by acting on JAK/STAT sign. [62-66]

Autophagy Enhancers

Wheat germ, soybean, and mushrooms contain spermidine, which is used as a compound that stimulates autophagy, or the self-cleaning process of cells that eliminates damaged proteins, lipids, and organelles to improve cell health and longevity, Autophagy an inhibition of acetyltransferase induces autophagy; resveratrol activates SIRT1 and AMPK indirectly to induce autophagy; EGCG activates autophagy through activation of AMPK; and ginsenoside from Panax g Increased autophagy gets

rid of intra-cellular debris, mitochondrial dysfunction, and oxidative stress, which are fundamental causes of age-related decline. The combination of senomorphics and autophagy inducing agents with anti-aging measures is an indication of a transition to the less cytotoxic measures of cellular reprogramming and cellular maintenance. The difficulties of aged and senescent physiology in ADMET CHALLENGES. [67-69]

ADMET CHALLENGES IN AGED AND SENESCENT PHYSIOLOGY

The term ADMET, which is an abbreviation of Absorption, Distribution, Metabolism, Excretion, and Toxicity, is a compilation of the most important pharmacokinetic and phycosodynamic events involved with the behavior of a drug in the body. These processes are dramatically changed by aging and cellular senescence, and the effects are dramatic. Safe and effective therapies in younger adults can cause uncertain effects, reduced efficacy, or greater toxicity in older adults.

Impact of Age-Related CYP450 Changes on Natural and Synthetic Agents

Changes in age involve the down-regulation of the expression of some of the CYP isoforms like CYP3A4 and CYP2C19 which slows the rate at which the drugs are metabolized and enhanced the plasma concentration of drugs with an accompanying risk of adverse reactions. Older people tend to be more reactive to CYP modulators, such as phytochemicals, and the risk of polypharmacy is also increased in most older patients on more than one drug.[67,68]

Relevance to natural products encompasses the capacity of curcumin to inhibit CYP3A4 and CYP2C9, which has the potential to increase the systemic exposure of the co-administered medication, grapefruit flavonoids that inhibit CYP3A4 and P-glycoprotein that changes bioavailability of cardiovascular medications, and green tea catechins that may increase metabolism of b-blockers and statins.[69] The dosing regimen of both synthetic senotherapeutics and natural products must take into consideration the metabolic It is usually safer to start with lower initial doses and then titrate gradually in the elderly.

Altered Tissue Distribution and Protein Binding in Aging



Figure.1. Disturbed tissue distribution and protein binding.

The aging process causes structural and functional alterations in gastrointestinal tract which has a direct impact on absorption and bioavailability of synthetic drugs and phytochemicals. Physiological alterations involve decreased acid secretion in the stomach which makes it less able to dissolve weakly basic substances, slower gastric emptying rate slows the rate of action, and less surface area in the intestine with less expression of nutrient transport molecules prevents the absorption of some vitamin, flavonoid, and amino acid-based medications.[70-71]

The effect on natural senotherapeutics is of special concern as quercetin and resveratrol are already low

intrinsic oral bioavailability drugs that could be aggravated by age-associated reduction in absorption. Polyphenols frequently experience excessive first-pass metabolism, potentially increased in elderly patients with altered gut microbiota composition.[72] Polyphenol formulation technologies, including liposomal encapsulation and solid lipid nanoparticles, co-administration with bioenhancers like piperine or sublingual or transdermal delivery which circumvents gastrointestinal limitations can be used.

Gut Microbiota Modulation of Natural Product Bioavailability

Having been absorbed, drugs and phytochemicals circulate around the body based on the composition of the tissues, blood circulation, and attachment to plasma proteins including albumin and a-1 acid glycoprotein. The process of aging changes all these parameters and affects both natural and synthetic senotherapeutics pharmacokinetics. The major changes in the elderly are heightened body fat percentage resulting in augmented apparent volume of distribution of lipophilic substances, decreased total body water leading to elevated plasma concentrations of hydrophilic medications, diminishing serum albumin with corresponding changes in the unbound active fraction and acid glycoprotein a-1, which binds basic pharmaceuticals and a few alkaloids.[73-75]

INTEGRATIVE STRATEGIES: BRIDGING PHARMACOGNOSY AND TRANSLATIONAL PHARMACOLOGY

The future of Senotherapeutics is in the marriage between the ancient pharmacogenetic wisdom and modern development pipeline of drugs. The untapped but rich store of bioactive compounds lies in natural products, and translational pharmacology provides the means to optimise, standardise, and clinicalise these compounds.

Leveraging Ethnopharmacology for Candidate Discovery

Indigenous, Unani, Traditional Chinese Medicine and Ayurveda Cultural pharmacopeias have been used as real-world high-throughput screens. Practical use history can be used to discover promising senolytic or senomorphic plants that have an established safety margin. Reverse pharmacology, beginning with clinical observation during conventional use and working backwards to isolate active compounds, can shorten discovery times, and decrease first stage attrition.[76]

Optimizing Formulation for Geriatric Pharmacokinetics

The use of bioavailability-promoting delivery systems such as liposomes, solid lipid nanoparticles and cyclodextrin complexes get around age-related absorption barriers. The ability to generate polyherbal-synthetic formulations that can synergize mechanisms and reduce toxicity by dose sparing and the formation of preparations that can be directed to route-specific benefits like transdermal patches of lipophilic antioxidants or sublingual sprays of highly first-pass metabolized polyphenols is promising.

Harmonizing Regulatory Pathways

Internationalization of botanical drug development to the global standards of WHO Traditional Medicine Strategy, ICH botanical drug quality frameworks, based on the standardized extracts containing validated marker compounds to fulfill pharmacopeial requirements, but maintain synergistic phytochemical profiles and dual classification approaches are some valuable steps to regulatory progress. Bringing together Systems Biology and Biomarker Platforms[77-79].

Integrating Systems Biology and Biomarker Platforms

The use of omics technologies such as metabolomics, proteomics, and transcriptomics is used to map the multi-target activities of plant-based senotherapeutics. Measuring intervention efficacy with geroscience biomarkers including the expression of p16INK4a, SASP cytokine panels, and epigenetic clocks, and creating adaptive clinical trial designs, which include biomarker readouts to adjust dosing in real time, especially in elderly populations with variable responses, is the future of personalized gerotherapeutics.[80]

CLINICAL TRANSLATION AND REGULATORY LANDSCAPE

The journey between bench discovery and bedside application of both natural and synthetic senotherapeutics is guided by regulatory frameworks, clinical trial design and the peculiarities of aging populations.

Clinical Translation Challenges

Older adult heterogeneous populations having vastly different functional reserve, comorbidity and polypharmacy cases complicate the standardization of trial outcomes. Regulatory agencies are putting increasingly greater emphasis on post-lifespan endpoints, looking at functional endpoints like mobility, cognitive functioning, and quality of life. The duration of trials that are used to age interventions is very long and high in cost and the probability of dropping out.

Regulatory Considerations

The complexity of the natural products complicates the process of standardizing and classifying multi-component plant extracts according to existing drug regulations. Numerous of the phytochemicals are sold as dietary supplements under minimum regulation, whereas geroprotective claims are the drug claims that need strict clinical testing. Inequality exists across the globe since the US FDA, European Medicines Agency, and Indian regulatory systems have different approaches to botanical drugs.[81-82]

Opportunities for Integration

Ethnopharmacology as a screening library with documented traditional use can inform choice of compounds and expedite pilot trials, adaptive trial designs with interim analysis and cohort modification, and combination therapy relationships between senolytics or senomorphics and lifestyle or dietary intervention may realise synergistic outcomes and enhanced regulatory acceptability.[83]

OUTSTANDING CONTROVERSIES AND FUTURE DIRECTIONS

Despite rapid progress in senotherapeutic research, several unresolved debates and practical obstacles continue to slow translation from concept to clinic.

Unresolved Scientific Questions

The ambiguous situation of mechanistic nature still remains because many natural products exhibit senolytic or senomorphic effects in vitro, but their targets in vivo and their long-term systemic effects are not well charted. The discussion is still ongoing as to whether or not polypharmacology of plant extracts with multiple action pathways is a strength or weakness over synthetic agents with specific actions. Existing aging biomarker systems such as epigenetic clocks and SASP cytokine panels are not yet universally accepted to make regulatory decisions, and therefore the endpoints of trials are not consistent.[84]

Regulatory and Classification Dilemmas

The botanical-pharmaceutical divide leads to a disjointed global approval process because the jurisdictions in which multi-component plant extracts are classified as dietary supplements or drugs vary globally. Although the traditional use was in favor of safety stories to maintain ethnopharmacological, it does not have randomized controlled trial information, which is the gold standard in regulations.[85]

Ethical and Safety Considerations

Issues of access and affordability are insider that because of senotherapeutic being expensive and a niche treatment, other interventions may increase disparities in health in aging populations. Self-medication risks are also present because the easy availability of concentrated plant extracts on the internet creates risks of misuse, interaction, and unchecked toxicity in the elderly group of consumers. The underlying answer remains on whether the increased lifespan without the functional independence is worth creating a greater burden of frailty.[86]

Future Directions

The ethnobotanists, pharmacologists, geroscientists and regulatory bodies should also be encouraged to collaborate in integrative research and development models so that they can simplify the discovery and approval process. Genomic and metabolomic profiling can be used to establish precision geropharmacology, which can suit an individual with the senotherapeutic most likely to be helpful. Hybrid senotherapeutics as semi-synthetic analogs of plant extracts preserve the ethnopharmacological origins and enhance pharmacokinetics and potency. Multinational, adaptive-design trials with adaptive global trials involving cultural context and biomarker endpoints are adaptive global trials that develop of robust evidence to enable regulatory acceptance.[87]

CHALLENGES AND FUTURE DIRECTIONS IN BIOMARKERS AND DOSING STRATEGIES

The translation of senotherapeutics from preclinical promise to clinical reality hinges on accurate biomarkers and optimized dosing paradigms, two domains still in early development.

Biomarker Limitations

Recent geroscience biomarkers, including epigenetic clocks, expression of p16INK4a, and SASP cytokine panels, are useful but not standardized to make regulatory decisions. The sensitivity and specificity of their detection in diverse tissues is different and most of them do not reflect the complexity of cellular senescence of heterogeneous aging populations. Clinical trials are exposed to lengthy timeframes and unclear results without the presence of trusted surrogate endpoints.[88]

Dosing Uncertainties

Senotherapeutics based on natural products can be even more complicated in that active phytochemicals tend to have non-linear pharmacokinetics, variable oral bioavailability and may have synergetic or antagonistic interactions in multi-component extracts. Synthetic senolytics are more predictable but might need pulse dosing to reduce off-target toxicity and retain, and even enhance, positive senescent cell functions. The development of dose-response relationships in comorbid populations among the older generation is a research gap that is of high priority.[89]

Future Priorities

Making tissue-specific and multimodal biomarker panels that combine molecular, imaging, and functional readouts, performing dose-finding studies in aging and disease-burdened cohorts instead of extrapolating them through young healthy volunteers, model-informed precision dosing platforms with consideration of patient-specific physiology and pharmacogenomics, and harmonizing biomarker standards across nations to allow data pooling and regulatory acceptability are all the key issues to focus on improving the field.[90]

MULTI-OMICS AND PERSONALIZED APPROACHES IN SENOTHERAPEUTICS

Aging biology is heterogeneous, and thus, no universal senotherapeutic approach will be effective. Multi-omics technologies such as genomics, transcriptomics, proteomics, metabolomics and epigenomics provide the way to precision geropharmacology, in which an individual aging pattern is the target of an intervention.

Personalized Mechanistic Insights

Using multi-omics data, researchers can map single senescence signatures, discover the major aging pathways and the senotherapeutic class is most likely to produce benefit, be it senolytic, senomorphic, autophagy enhancer or hybrid. Such information-based stratification also has the capability to show off-target vulnerabilities prior to initiation of treatment which allows therapeutic optimization which optimizes the choice of compounds, combination therapy design and can be used to monitor early how the molecular response.[91]

Challenges in Implementation

The complexity and the cost of data continues to be a significant obstacle especially in large and heterogeneous aging populations. Omics workflows must be standardized to guarantee interlaboratory and interclinic reproducibility. It must also be integrated with clinical endpoints, in order that molecular changes can be converted into quantifiable functional benefits.[92]

Future Outlook

As computational biology advances, coupling multi-omics profiling with AI-driven predictive modeling could allow real-time treatment adjustments, ushering in an era where senotherapeutics are prescribed not as generalized anti-aging drugs but as personalized healthspan modulators. Pharmacogenomic profiling of variations in drug-metabolizing enzymes, drug transporters, and senescence-related pathways enables patient stratification for personalized dosing, especially in elderly patients with polymorbidity. [93]

ETHICAL CONSIDERATIONS IN ANTI-AGING THERAPEUTICS

The field of senotherapeutics faces distinctive ethical challenges due to the novelty and complexity of targeting aging itself.

Informed Consent and Risk Communication

With the growth of computational biology, integrating multi-omics profiling and AI-based predictive modeling may permit real-time changes in treatment, which may mark the dawn of senotherapeutics being prescribed as custom healthspan regulators and not as anti-aging drugs in

general. Patient stratification based on personalization of drug dosing by pharmacogenomic profiling of changes in drug-metabolizing enzymes, drug transporters, and senescence-related pathways, can be applied to older patients with polymorbidity. Ethical issues in anti-aging therapy. [94-95]

Equity and Access Issues

Senotherapeutics experiences unique ethical concerns because the problem of attacking aging (as opposed to attacking age-associated diseases) is new and unique.

Regulatory and Oversight Complexity

The sphere of aging interventions does not contain a clear line of distinction between prevention and other approaches as well as between therapy and enhancement, hence it cannot be easily categorized as a single-disease-specific drug, per the current regulatory models. This demands new, adaptive principles of protecting safety and facilitating innovation.[96]

Existing Ethical Frameworks and Guidelines

Ethical Governance Principles adapted to biomedical innovation by WHO focus on fairness, transparency and benefit to the society. The Nuffield Council on Bioethics advises on aging research, with more emphasis given to patient-centered studies and ethical principle of autonomy, beneficence, non-maleficence, and justice.[97]

Recommendations for Ethical Integration

The trial design, approval, and post-market surveillance must be directed by multidisciplinary oversight committees who have panels of clinicians, ethicists, patient advocates, and regulators. Open citizen intervention via systematic and continuous communication forms social acceptance of the objectives and limits of life-extension technology. Adaptive consent models enable participants to update or renew consent with the emergence of new information. Policies based on equity such as subsidy programs, expansion of insurance coverage, and research funding to the underrepresented and vulnerable groups guarantees equitable access.[98]

CONCLUSION

As a leader in geroscience, senotherapeutics have the potential to slow, mitigate or even reverse major factors that cause natural aging. The natural products, which are based on the thousand-year-old ethnopharmacological experience, offer a huge and chemically diversified pool of bioactive agents, whereas the synthetic compounds also allow specificity in the engagement of a target. It will take not just the pharmacological discovery to bridge these two domains but also regulatory innovation, ethical stewardship, and translational approaches that would be responsive to the complexity of aging biology. The most effective way ahead will be incorporating some of the traditional knowledge systems of identifying the candidates, state of the art formulation technologies to overcome the bioavailability constraints and systems biology platforms to map the multi-target effects of the senotherapeutics. Advancement will also be pegged on the establishment of good, validated biomarkers, adaptive clinical trial models, and fair access policies that will help extend the life span of these therapies as well as the healthspan. Overcoming the problem of botanical variability with standardization guidelines, exploiting natural product diversity and utilizing synthetic accuracy by means of integrative therapeutic approaches, and establishing tailored medicine models by means of multi-omics and pharmacogenomic characterization are all of the most urgent priorities to the field. The potential of extending healthy human lifespan can be taken responsibility only by addressing scientific, regulatory, ethical, and accessibility issues simultaneously with the mechanistic and pharmacological studies. When approached with scientific integrity and social accountability, the merging of pharmacognosy and translational pharmacology can make healthy aging a far-off dream a clinical possibility of various people all over the world.

ACKNOWLEDGMENTS

The authors acknowledge the institutional support and access to digital resources that enabled the completion of this work.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest related to the content of this manuscript.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217.
2. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-13.
3. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21(12):1424-35.
4. Kirkland JL, Tchkonia T. Cellular senescence: translational perspective. EBioMedicine. 2017;21:21-8.
5. Pan MH, Lai CS, Ho CT. Anti-inflammatory activity of natural dietary flavonoids. Food Funct. 2010;1(1):15-31.
6. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2(12):1231-46.
7. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons from clinical trials. AAPS J. 2013;15(1):195-218.
8. Wang Z, Chen X, Lu Y, Chen Z, Gui C. Resveratrol: a review of plant sources, biosynthesis, pharmacological activities. Crit Rev Food Sci Nutr. 2019;59(3):283-96.
9. Ganesan K, Xu B. Polyphenols and health benefits of black soybean. Nutrients. 2017;9(4):455.
10. Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377-98.
11. Gomes AP, Price NL, Ling AJY, et al. Declining NAD+ induces pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-38.
12. Rocha JB, Souza DP, Emanuelli T, et al. Medicinal and aromatic plants: traditional uses in Brazilian folk medicine. Fundam Clin Pharmacol. 2018;32(6):621-34.
13. Kim H, Kim S, Lee J, et al. Ethnopharmacology, phytochemistry and pharmacology of Ginkgo biloba. Phytochem Rev. 2021;20:375-418.
14. Kuznetsova AV, Kekelidze T, et al. Mitochondrial antioxidant restores mtDNA quality. Aging Cell. 2019;18(5):e13061.
15. de Magalhães JP, Stevens M, Thornton D. The business of anti-aging science. Trends Biotechnol. 2017;35(8):774-83.
16. Schafer MJ, Miller JD, LeBrasseur NK. Targeting senescent cells in fibrosis: translational implications. Nat Rev Rheumatol. 2020;16(10):569-79.
17. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69 Suppl 1:S4-9.
18. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-58.
19. Roos CM, Zhang B, Palmer AK, et al. Chronic senolytic treatment alleviates vasomotor dysfunction in aged mice. Aging Cell. 2016;15(5):973-7.
20. Schafer MJ, White TA, Iijima K, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8:14532.
21. He S, Sharpless NE. Senescence in health and disease. Cell. 2017;169(6):1000-11.
22. Demaria M, O'Leary MN, Chang J, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7(2):165-76.
23. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR as key modulator of aging. Nature. 2013;493(7432):338-45.
24. Hurez V, Palomba L, Obba S, et al. Clearance of senescent cells by ABT263 rejuvenates hematopoietic stem cells. Nat Med. 2021;27(3):446-50.
25. Kirkland JL, Tchkonia T. Senolytic therapies for healthy longevity. Science. 2017;355(6330):eaah3718.
26. Gilroy DW, Bishop-Bailey D. Complementing anti-aging with anti-inflammatory strategies: senolytics, SASP modulators, and immunotherapies. Ageing Res Rev. 2020;62:101103.

27. Bussian TJ, Aziz A, Meyer CF, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562(7728):578-82.
28. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: first human pilot study. EBioMedicine. 2019;40:554-63.
29. Kirkland JL, Tchkonia J. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.
30. Nikolich-Žugich J. Twilight of immunity: emerging concepts in immune aging. Nat Immunol. 2018;19(1):10-9.
31. Ferrucci L, Fabbri E. Inflammageing in cardiovascular disease and frailty. Nat Rev Cardiol. 2018;15(9):505-22.
32. Linterman MA, Hill DL. Senescent cells accelerating immunosenescence. Nat Rev Immunol. 2023;23(12):818-30.
33. Trifunovic A, Larsson NG. Mitochondrial dysfunction in aging. Biochim Biophys Acta. 2008;1777(7-8):673-6.
34. Mitrofanis J. Mitochondrial function and neurodegeneration. Aging Dis. 2010;1(2):130-49.
35. Xu M, Tchkonia T, Ding H, et al. Targeting senescent cells enhances adipogenesis and metabolic function. Elife. 2015;4:e12997.
36. Barzilai N, Gorbunova V, Sinclair D. Long-lived animal models and health-span extension in studies of aging. Innov Aging. 2017;1(Suppl 1):10.
37. Singh N, Aggarwal BB. Activation of transcription factor NF-κB suppressed by curcumin. J Biol Chem. 1995;270(42):24995-5000.
38. Li W, Tang Y, Wang H, et al. Traditional uses and pharmacology of Sophora japonica. Phytomedicine. 2020;70:153221.
39. Martens CR, Denman BA, Mazzo MR, et al. Chronic supplementation of nicotinamide riboside elevates NAD+. Nat Commun. 2018;9(1):1286.
40. Manikyam HK, Patil AR, et al. High-throughput in-silico drug screen against Mpox. *J Pharm Res Int*. 2024;36(11):41-52. doi:10.9734/jpri/2024/v36i114570.
41. Manikyam HK, Patil AR, et al. Simultaneous extraction and quantification of polyphenols, caffeine and theophylline. *South Asian Res J Nat Prod*. 2024;7(3):401-413. doi:10.9734/sarjn/2024/v7i3110.
42. Manikyam HK, Patil AR, et al. Altered lipid metabolism in cancer: A review. *Diseases Res*. 2024;4(2):97-107. doi:10.9734/dr/2024/v4i2125.
43. Malla MA, Patil AR, et al. Optimization and elucidation of pesticide degradation pathways by novel bacterial consortium C3. *J Taiwan Inst Chem Eng*. 2023;144:104744. doi:10.1016/j.jtice.2023.104744.
44. Munot N, Patil AR, et al. A comparative study of quercetin-loaded nanocochleates and liposomes: formulation, characterization, assessment of degradation and in vitro anticancer potential. *Pharmaceutics*. 2023;14(8):1601. doi:10.3390/pharmaceutics14081601.
45. Das N, Patil AR, et al. Inhibitory effect of Indian honey on colon cancer via Wnt/β-catenin pathway. *Food Funct*. 2022;13(15):8283-8303. doi:10.1039/D2FO01090K.
46. Manikyam HK, Patil AR, et al. Hesperidin extraction from immature *Citrus grandis*. *Asian J Nat Prod Biochem*. 2022;20(1):xx-xx. doi:10.9734/ajnpb/2022/v20i1105.
47. Nalawade AS, Patil AR, et al. Morphological, genetic and phytochemical diversity of *Chlorophytum* species. *Trends Phytochem Res*. 2022;6(1):19-45. doi:10.22034/tpri.2022.530486.
48. Munot N, Patil AR, et al. Mucoadhesion, permeation and anticancer potential of thiolated gums. *Molecules*. 2022;27(20):6829. doi:10.3390/molecules27206829.
49. Patil AR, et al. Banana fibers camouflaging as gut worm in infant. *Iberoam J Med*.

2020;2(3):245-247. doi:10.5281/zenodo.3842339.
50. Patil AR, et al. Genome sequence of *Lactobacillus plantarum* JDARSH. *Microbiol Resour Announc*. 2020;9(2):e01234-19. doi:10.1128/MRA.01234-19.
51. Abhinandan PSP, et al. Probiotic potential of *Lactobacillus plantarum*. *J Global Pharma Technol*. 2019;10(12):1-6. doi:10.5281/zenodo.3552379.
52. Patil AR, et al. Shelf-life stability of encapsulated lactic acid bacteria. *Small Rumin Res*. 2019;170:19-25. doi:10.1016/j.smallrumres.2018.12.010.
53. Patil AR, et al. Granules of unistrain *Lactobacillus* as nutraceutical antioxidant. *Int J Pharm Sci Res*. 2018;9(4):1594-1599. doi:10.13040/IJPSR.0975-8232.9(4).1594-99.
54. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.
55. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR as key modulator of aging. Nature. 2013;493(7432):338-45.
56. Wightman JD, Villemagne VL, Rowe CC, et al. Pharmacokinetics of rapamycin in elderly adults: challenges. Clin Pharmacol Ther. 2020;108(3):485-93.
57. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons from clinical trials. AAPS J. 2013;15(1):195-218.
58. Wang Z, Chen X, Lu Y, Chen Z, Gui C. Resveratrol: a review of plant sources, biosynthesis, pharmacological activities. Crit Rev Food Sci Nutr. 2019;59(3):283-96.
59. Rocha JB, Souza DP, Emanuelli T, et al. Medicinal and aromatic plants: traditional uses in Brazilian folk medicine. Fundam Clin Pharmacol. 2018;32(6):621-34.
60. Kim H, Kim S, Lee J, et al. Ethnopharmacology, phytochemistry and pharmacology of Ginkgo biloba. Phytochem Rev. 2021;20:375-418.
61. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2(12):1231-46.
62. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.
63. Singh N, Aggarwal BB. Activation of transcription factor NF-κB suppressed by curcumin. J Biol Chem. 1995;270(42):24995-5000.
64. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69 Suppl 1:S4-9.
65. Ferrucci L, Fabbri E. Inflammageing in cardiovascular disease and frailty. Nat Rev Cardiol. 2018;15(9):505-22.
66. López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic control of longevity. Cell. 2016;166(4):802-21.
67. Trifunovic A, Larsson NG. Mitochondrial dysfunction in aging. Biochim Biophys Acta. 2008;1777(7-8):673-6.
68. Mitrofanis J. Mitochondrial function and neurodegeneration. Aging Dis. 2010;1(2):130-49.
69. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2(12):1231-46.
70. Wightman JD, Villemagne VL, Rowe CC, et al. Pharmacokinetics of rapamycin in elderly adults: challenges. Clin Pharmacol Ther. 2020;108(3):485-93.
71. López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic control of longevity. Cell. 2016;166(4):802-21.
72. Rai R, Mookerjee A, Eissa N. Challenges for NAD+ precursor use in metabolic disease and cancer. Pharmacol Ther. 2021;221:107766.
73. Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377-98.

74. Trifunovic A, Larsson NG. Mitochondrial dysfunction in aging. Biochim Biophys Acta. 2008;1777(7-8):673-6.
75. López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic control of longevity. Cell. 2016;166(4):802-21.
76. Rocha JB, Souza DP, Emanuelli T, et al. Medicinal and aromatic plants: traditional uses in Brazilian folk medicine. Fundam Clin Pharmacol. 2018;32(6):621-34.
77. Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377-98.
78. de Magalhães JP, Stevens M, Thornton D. The business of anti-aging science. Trends Biotechnol. 2017;35(8):774-83.
79. Kirkland JL, Tchkonia J. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.
80. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69 Suppl 1:S4-9.
81. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: first human pilot study. EBioMedicine. 2019;40:554-63.
82. Kirkland JL, Tchkonia J. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.
83. Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377-98.
84. Kaplan HJ, Schmitz-Valckenberg S, et al. Translational gap: preclinical models vs human aging. Aging Cell. 2022;21(3):e13534.
85. Kirkland JL, Tchkonia J. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.
86. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: first human pilot study. EBioMedicine. 2019;40:554-63.
87. Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377-98.
88. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21(12):1424-35.
89. Kirkland JL, Tchkonia J. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.
90. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21(12):1424-35.
91. López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic control of longevity. Cell. 2016;166(4):802-21.
92. Kaplan HJ, Schmitz-Valckenberg S, et al. Translational gap: preclinical models vs human aging. Aging Cell. 2022;21(3):e13534.
93. López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic control of longevity. Cell. 2016;166(4):802-21.
94. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: first human pilot study. EBioMedicine. 2019;40:554-63.
95. Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377-98.
96. Kirkland JL, Tchkonia J. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-36.
97. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: first human pilot study. EBioMedicine. 2019;40:554-63.
98. Niedernhofer LJ, Robbins PD. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377-98.